Research Park News

July 13, 2017

On Target Laboratories’ cancer illuminating technology receives Special Protocol Assessment from FDA

On Target compound OTL38, a product of On Target Laboratories LLC is a novel compound that binds with diseased tissue present in several cancers, making it light up, or fluoresce, during cancer surgery. (On Target Laboratories LLC photo) Download image

WEST LAFAYETTE, Ind. – On Target Laboratories LLC, a company developing a unique fluorescent imaging technology that could help surgeons identify and remove more cancerous tissue, has received Special Protocol Assessment approval from the Food and Drug Administration for its Phase 3 ovarian cancer intraoperative imaging clinical trial.

The company anticipates beginning enrollment for the clinical trial in October, 2017. On Target previously received FDA designation for a fast track development program for the OTL38 compound in ovarian cancer patients.

"We are excited to be entering the next stage of development of our intra-optical imaging molecule OTL38 for the benefit of ovarian cancer patients. It is our goal to help surgeons see and remove additional cancer lesions they would have otherwise missed,” said Marty Low, On Target Laboratories CEO. “Our work aims to remove as much of the cancer as possible during surgery to ensure ovarian cancer patients live longer, healthier lives."

On Target’s lead compound, OTL38 is a novel compound that binds with diseased tissue present in several cancers, making it light up, or fluoresce, during cancer surgery. The compound aims to help surgeons pinpoint and more accurately remove cancerous tissues while preserving healthy tissue in patients.

On Target Laboratories is headquartered at the Purdue Research Park of West Lafayette.

About On Target Laboratories LLC

On Target Laboratories LLC is in the business of discovering, developing and commercializing small molecules that, when conjugated with fluorescent dyes, target and illuminate specific cancerous cells and other diseased tissue. These conjugates can be used by doctors, including surgeons, worldwide to better diagnose and treat a wide range of diseases from cancer to inflammation-related disorders.

About Purdue Research Park

The Purdue Research Park is the largest university-affiliated business incubation complex in the country. The Purdue Research Park manages the Purdue Technology Centers at four sites in Indiana, located in West Lafayette, Indianapolis, Merrillville and New Albany. The more than 260 companies located in the park network employ about 4,500 people who earn an average annual wage of $63,000. The park is managed by the Purdue Research Foundation, which received the 2014 Incubator Network of the Year from the National Business Incubator Association for its work in entrepreneurship. For more information about funding and investment opportunities in startups based on a Purdue innovation, contact the Purdue Foundry at

Purdue Research Foundation contact: Hillary Henry, 765-588-3586,

On Target Laboratories LLC contact: Erin Nichols,

Elizabeth Estes, 313-749-9323,

Research Park News

Purdue University, 610 Purdue Mall, West Lafayette, IN 47907, (765) 494-4600

© 2015-22 Purdue University | An equal access/equal opportunity university | Copyright Complaints | Maintained by Office of Strategic Communications

Trouble with this page? Disability-related accessibility issue? Please contact News Service at